Vanda Pharmaceuticals (VNDA) to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.18) per share for the quarter.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The firm had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.74 on Thursday. The firm has a market cap of $276.29 million, a price-to-earnings ratio of -24.00 and a beta of 0.77. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The firm has a 50-day moving average price of $4.86 and a two-hundred day moving average price of $5.23.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Cantor Fitzgerald increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $18.00 target price for the company. Finally, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 24th. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.